Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1901-1920 of 2,120 trials

Esophageal Cancer: Tislelizumab for Elderly Patients

We are studying Tislelizumab to see if it helps elderly patients with advanced esophageal cancer who cannot receive chemotherapy. The trial aims to assess survival rates and quality of life improvements.

Esophageal Squamous Cell Carcinoma3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Acute Myeloid Leukemia: L-Annamycin with Cytarabine

We are studying a new treatment combining L-Annamycin with Cytarabine for adults with difficult-to-treat acute myeloid leukemia. The goal is to see if this combination can help achieve remission better than a placebo.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteOncology

HER2-Positive Metastatic Breast Cancer: [177Lu]Lu-ABY-271 Treatment

We are studying a new treatment to see if it is safe and how it distributes in the body for patients with HER2-positive metastatic breast cancer. This trial will help us understand its effects on tumors and normal organs.

HER2-positive Metastatic Breast Cancer3-6 monthsSafety phase (I)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Chronic Inflammatory Demyelinating Polyneuropathy: Batoclimab Study

We are studying the long-term safety and tolerability of batoclimab in adults with CIDP. This trial aims to see how well the medication works for managing symptoms over time.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Lung Cancer Treatment: Divarasib and Pembrolizumab

We are studying a new treatment combination for patients with advanced non-small cell lung cancer that has a specific genetic mutation. The goal is to see if this new approach improves survival and quality of life compared to standard treatments.

Advanced Non-Squamous Non-Small Cell Lung Cancer1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Wiskott-Aldrich Syndrome: Long-term Study of Gene Therapy

We are examining the long-term safety and effectiveness of a gene therapy treatment for individuals with Wiskott-Aldrich Syndrome. This study aims to provide insights into how well the treatment works over time.

Wiskott-Aldrich Syndrome>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteHematologyInfectious Diseases

Leber Congenital Amaurosis: Sepofarsen Treatment Study

We are investigating a new treatment for people with Leber Congenital Amaurosis caused by a specific genetic mutation. The study will assess how well it improves vision and its safety over time.

Leber's Congenital Amaurosis>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesOphthalmology

Neuroinflammation in Major Depressive Disorder: InflaDep Study

We are investigating the patterns of neuroinflammation in people with major depressive disorder compared to those in remission and healthy individuals. This study may help us understand the links between inflammation and depression symptoms.

Depressive Disorder>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesPsychiatry

Ketamine for Treating Disorders of Consciousness After Coma

We are studying whether intravenous ketamine can help patients regain consciousness after a coma. The trial also aims to identify which patients may respond best to this treatment.

Severe Brain Injury and Disorder of Consciousness>2 yearsEfficacy phase (II)Standard MedicinesPartially RemoteNeurologyPsychiatry

Ulcerative Colitis: Tofacitinib's Impact on Blood Clotting

We are studying how tofacitinib affects blood clotting and platelet function in patients with ulcerative colitis. This trial also compares its effects to other treatments and collects samples for future research.

Ulcerative Colitis3-6 monthsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyHematology

Cerebral Palsy: IncobotulinumtoxinA Treatment

We are studying the safety and effectiveness of IncobotulinumtoxinA for children with upper and lower limb spasticity due to cerebral palsy. This trial includes both new and previously treated patients to see how well the treatment works.

Muscle Spasticity1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesNeurologyPediatrics

Neovascular Age-Related Macular Degeneration: AI-Assisted Treatment

We are exploring how artificial intelligence can help improve treatment for patients with active neovascular AMD. This study aims to make the treatment process easier for patients and healthcare providers.

Neovascular Age-Related Macular Degeneration1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOphthalmology

Ischemic Stroke: Thrombolytic Therapy with rtPA

We are studying a new treatment for patients with acute ischemic stroke who are on blood thinners. The goal is to see if this therapy improves recovery compared to a placebo after reversing the blood thinner's effects.

Ischaemic Stroke3-6 monthsEfficacy phase (II)≤5 visitsStandard MedicinesPartially RemoteInternal MedicineNeurology

Colorectal Cancer: Intravenous Iron Infusion Study

We are investigating whether intravenous iron can improve physical capacity and immune response in non-anemic patients with colorectal cancer. This study compares the effects of iron to a placebo to understand its potential benefits.

Iron Deficiency>2 yearsEfficacy phase (II)Investigational MedicinesGastroenterologyOncology

Allergic Rhinitis: New Immunotherapy Treatment

We are studying a new subcutaneous immunotherapy for patients with allergic rhinitis or rhinoconjunctivitis, with or without asthma. The goal is to evaluate its safety and effectiveness compared to a placebo.

Moderate to Severe Allergic Rhinitis with or without Asthma1-2 yearsEfficacy phase (II)Standard MedicinesAllergologyInternal Medicine

Early Alzheimer’s Disease: AD04 Treatment Study

We are testing a new treatment called AD04 to see if it can slow the progression of early Alzheimer’s disease. The study will also evaluate the safety of AD04 and its effects on quality of life.

Early Alzheimer's Disease>2 yearsEfficacy phase (II)Investigational MedicinesNeurologyPsychiatry

Metastatic Colorectal Cancer: Cetuximab Treatment Study

We are exploring a new treatment approach using cetuximab for patients with specific genetic markers in metastatic colorectal cancer. The study aims to understand its effectiveness, safety, and impact on quality of life.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Breast MRI: Low-Dose Gadolinium Study

We are testing whether a lower dose of gadolinium in breast MRI can provide image quality similar to the standard dose. This may help reduce contrast exposure while maintaining diagnostic accuracy.

Breast Cancer1-2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboInvestigational MedicinesInternal MedicineOncologyOtolaryngology

Antibiotic Levels in Pregnant Women with Twins

We are studying how antibiotics are processed in mothers of twins and their newborns. This research may help improve treatment safety and effectiveness for both mothers and babies.

Pregnancy≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsInfectious Diseases

Hematopoietic Cell Transplantation: Comparing Conditioning Regimens

We are comparing two treatment methods for patients receiving stem cell transplants from matched donors. The goal is to see if one method improves recovery rates better than the other.

Hematological Malignancies>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology